Sign inJoin waitlistJoin the waitlist

DB

Daniel Bradford

Physician · Highlands Oncology Group Pa

Credentials: · ·

History

Highlands Oncology Group Pa
2019–Present

Hematology and Medical Oncology
1986–1989
Internal Medicine
1983–1986
Univ of Arkansas Coll of Med
1979–1983

Research

An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)
Lung Cancer · 2017 · 49 citations
A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell…
Journal of Thoracic Oncology · 2011 · 32 citations
Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy
Cancer · 2020 · 13 citations

MS
Mark Socinski
4 papers
Carrie Lee
2 papers
JC
Jeffrey Crane
2 papers
KB
Kamal Bakri
2 papers
TH
Thomas Hensing
2 papers
Thomas Stinchcombe
2 papers
AS
Alan Sallman
1 paper
BJ
Bruce Johnson
1 paper
Chad Pecot
1 paper
DM
Daniel Morgensztern
1 paper
DE
David Ellison
1 paper
DL
David Lipschitz
1 paper